Anuh Pharma Ltd

The transcript does not explicitly mention the current or expected order book or pending orders for Anuh Pharma Limited. However, some relevant points that indirectly relate to orders and market expectations include: - The company expects fast growth in key products like Azithromycin, Sulfadoxine, and Gliclazide in the next 2 years. - Regulatory sales, including European approvals and WHO prequalification products, are expected to increase year-on-year by at least 10%. - The expanded manufacturing capacity is planned to increase from 1200 MT to 1500 MT during FY22, with utilization expected to reach around 80-85% by FY22-23. - The company is targeting 20-25% year-on-year top-line growth over the next 4-5 years. - They have been able to maintain a broad client base of approximately 350 customers to ensure steady demand. - No specific numeric order book or pending order values are disclosed in the transcript.

- There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript. - The company is focusing on organic growth, including capacity expansion (from 1200 to 1500 metric tonnes) and product development. - There are plans for inorganic growth via acquisitions, but only if the right candidate is found; no fundraising details were shared. - The company is studying the listing criteria for NSE, expected to take 6-9 months, but no mention of raising equity in this context. - Overall, the management emphasizes internal cash flows and investment plans funded through own means rather than government schemes or external fundraising. Therefore, based on the transcript, there is no announced or planned debt or equity fundraising at this time.

- During FY 2021-22, Anuh Pharma plans to invest an additional ₹4 crores in capital expenditure. - This capex aims to increase manufacturing capacity from 1,200 metric tonnes per year to 1,500 metric tonnes. - The company had previously spent around ₹70 crores for expansion commissioned in December 2019. - There are ongoing validation batches and R&D activities on new products like Gliclazide, Ambroxol Hydrochloride, and Sulfadoxine at the new plant. - The company is also exploring inorganic growth through acquisitions but is yet to identify the right candidate; the plan is to pursue this within the next 1.5 years. - No current plans for entering CRAMS (Contract Research and Manufacturing Services); focus remains on API manufacturing.

- The company expects a 20% to 25% year-on-year growth in top line (sales/revenue) over the next 4 to 5 years. - New products are targeted to contribute at least 25% of total revenue within the next 3 years. - Quantity-wise sales in regulated markets are expected to increase progressively year-on-year, with regulatory products currently contributing 17.5% and expected to grow 10% annually. - Capacity expansion plans include increasing manufacturing capacity from 1200 to 1500 metric tonnes by FY22, aiming for 80-85% utilization by 2023. - Fastest growing products anticipated over 2 years: Azithromycin, Sulfadoxine, and Gliclazide. - The company plans a 30% growth in top line and bottom line post recent expansions, maintaining an EBITDA margin around 15%. - Ambroxol approved for European regulatory markets; more regulatory approvals expected in 3-4 years post validation.

- The company expects top line growth of 20% to 25% year-on-year for the next 4-5 years. - EBITDA margin target is around 15%, with an average EBITDA margin of 15% already achieved in FY21 despite higher depreciation. - For FY22, management conservatively expects 25-30% growth in both top line and bottom line. - New regulatory product sales are expected to grow about 10% year-on-year, with regulatory sales already contributing 17.5% and expected to increase to 25%. - Profit margins on regulatory sales are higher, with EBITDA margins of 30-35% vs 14-15% for non-regulatory sales. - Expansion plans include increasing capacity from 1200 to 1500 metric tonnes by FY22, aiming for 80-85% utilization. - The management is confident of continuing steady growth in profits and EPS driven by new product launches and increased regulatory market penetration.